Identifying Genetic Predictors of Durable Clinical Benefit to Pembrolizumab in Advanced Non-small Cell Lung Cancer Alone and in Combination With Chemotherapy.

Trial Profile

Identifying Genetic Predictors of Durable Clinical Benefit to Pembrolizumab in Advanced Non-small Cell Lung Cancer Alone and in Combination With Chemotherapy.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Bladder cancer; Head and neck cancer; Non-small cell lung cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Nov 2017 Planned number of patients changed from 120 to 90.
    • 28 Mar 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 18 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top